{"id":"turoctocog-alfa","rwe":[],"tags":[{"label":"Biologic","category":"modality"},{"label":"B02BD02","category":"atc"},{"label":"Active","category":"status"},{"label":"Hereditary factor VIII deficiency disease","category":"indication"},{"label":"Novo Nordisk A/S","category":"company"}],"phase":"marketed","safety":{"safetySignals":[{"llr":33.137,"date":"","count":3,"signal":"Carotid artery dissection","source":"DrugCentral FAERS","actionTaken":"Reported 3 times (LLR=33)"}],"commonSideEffects":[{"effect":"Inhibitors in Previously Untreated Patients (PUPs)","drugRate":"42.9%","severity":"common","organSystem":""},{"effect":"High titer inhibitors (≥5 BU) in PUPs","drugRate":"26.8%","severity":"common","organSystem":""},{"effect":"Injection site reaction","drugRate":"1%","severity":"common","organSystem":""},{"effect":"Pyrexia","drugRate":"1%","severity":"common","organSystem":""}],"seriousAdverseEvents":[]},"trials":[],"aliases":[],"company":"Novo Nordisk","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=TUROCTOCOG ALFA","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T03:30:43.404899+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T03:30:50.425051+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-20T03:30:43.427180+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=TUROCTOCOG ALFA","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T03:30:51.101424+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Coagulation factor VIII exogenous protein","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:30:51.773871+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2108286/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:30:51.685384+00:00"}},"allNames":"novoeight","offLabel":[],"synonyms":["turoctocog alfa","turoctocog alfa (genetical recombination)","novoeight","coagulation factor VIII"],"timeline":[{"date":"2013-11-13","type":"positive","source":"DrugCentral","milestone":"EMA approval (Novo Nordisk A/S)"},{"date":"2014-01-17","type":"positive","source":"DrugCentral","milestone":"PMDA approval (Novo Nordisk Pharma Ltd.)"}],"aiSummary":"Novoeight is a recombinant exogenous protein used to treat Congenital Bleeding Disorder and Haemophilia A. It works by replacing the missing or deficient Coagulation factor VIII in the body.","approvals":[{"date":"2013-11-13","orphan":false,"company":"Novo Nordisk A/S","regulator":"EMA"},{"date":"2014-01-17","orphan":false,"company":"Novo Nordisk Pharma Ltd.","regulator":"PMDA"}],"brandName":"Novoeight","ecosystem":[{"indication":"Hereditary factor VIII deficiency disease","otherDrugs":[{"name":"desmopressin","slug":"desmopressin","company":"Ferring Pharms Inc"},{"name":"emicizumab","slug":"emicizumab","company":"Genentech Inc"},{"name":"vasopressin","slug":"vasopressin","company":"Parke Davis"}],"globalPrevalence":null}],"mechanism":{"modality":"Biologic","explanation":"","oneSentence":"","technicalDetail":"Novoeight is a recombinant DNA-derived antihemophilic factor VIII product that contains the B-domain-deleted form of human factor VIII, which is produced through a mammalian cell culture system and purified using a series of chromatographic steps."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/5019","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=TUROCTOCOG%20ALFA","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=TUROCTOCOG ALFA","fields":["publications"],"source":"PubMed/NCBI"}],"_emaChecked":true,"_enrichedAt":"2026-03-30T16:10:42.058359","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:30:53.559406+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"vonicog alfa","drugSlug":"vonicog-alfa","fdaApproval":"2015-12-08","relationship":"same-class"}],"genericName":"turoctocog alfa","indications":{"approved":[{"name":"Hereditary factor VIII deficiency disease","source":"DrugCentral","snomedId":28293008,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"vonicog-alfa","brandName":"vonicog alfa","genericName":"vonicog alfa","approvalYear":"2015","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT06579144","phase":"PHASE1","title":"Pharmacokinetic Comparison of Efanesoctocog Alfa vs Other EHL-rFVIII Products in Participants With Severe Haemophilia A","status":"RECRUITING","sponsor":"Swedish Orphan Biovitrum","startDate":"2025-02-24","conditions":["Hemophilia A"],"enrollment":24,"completionDate":"2026-05-28"},{"nctId":"NCT06574984","phase":"","title":"Study for Turoctocog Alfa Treatment Regimen in Iraqi Haemophilia A Patients","status":"RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2024-11-10","conditions":["Congenital Bleeding Disorder","Haemophilia A"],"enrollment":900,"completionDate":"2026-04-30"},{"nctId":"NCT05082116","phase":"PHASE3","title":"Efficacy and Safety of Turoctocog Alfa Pegol (N8-GP) for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Chinese Patients With Haemophilia A (pathfinder10)","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2021-09-27","conditions":["Haemophilia A"],"enrollment":36,"completionDate":"2022-12-28"},{"nctId":"NCT02137850","phase":"PHASE3","title":"Safety and Efficacy of Turoctocog Alfa Pegol (N8-GP) in Previously Untreated Patients With Haemophilia A","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2014-06-26","conditions":["Congenital Bleeding Disorder","Haemophilia A"],"enrollment":124,"completionDate":"2023-06-07"},{"nctId":"NCT04574076","phase":"","title":"A Study Following Males With Haemophilia A on Prophylaxis With Esperoct®","status":"ENROLLING_BY_INVITATION","sponsor":"Novo Nordisk A/S","startDate":"2020-10-23","conditions":["Haemophilia A"],"enrollment":60,"completionDate":"2027-06-03"},{"nctId":"NCT04682145","phase":"","title":"Adverse Event Data Collection From the EUHASS Registry on Turoctocog Alfa Pegol","status":"ENROLLING_BY_INVITATION","sponsor":"Novo Nordisk A/S","startDate":"2020-12-09","conditions":["Haemophilia A"],"enrollment":50,"completionDate":"2026-02-01"},{"nctId":"NCT04334057","phase":"","title":"Post-Marketing Surveillance (Use-results Surveillance) With Esperoct®","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2021-03-31","conditions":["Haemophilia A"],"enrollment":23,"completionDate":"2024-01-10"},{"nctId":"NCT05621746","phase":"","title":"An Observational Research Study of the Health of Joints in People With Haemophilia Taking the Medicine Esperoct","status":"RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2022-11-23","conditions":["Haemophilia A"],"enrollment":100,"completionDate":"2026-06-30"},{"nctId":"NCT04584892","phase":"","title":"Turoctocog Alfa in Haemophilic Italian Patients: Protection and Engagement in Recreational Activities","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2021-04-12","conditions":["Haemophilia A"],"enrollment":18,"completionDate":"2023-03-27"},{"nctId":"NCT03528551","phase":"PHASE3","title":"A Research Study Looking at How a Factor VIII Medicine Called Turoctocog Alfa Pegol (N8-GP) Works in People With Haemophilia A","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2018-04-30","conditions":["Congenital Bleeding Disorder","Haemophilia A"],"enrollment":160,"completionDate":"2020-12-03"},{"nctId":"NCT04808349","phase":"","title":"Safety and Efficacy in a ReAl-Life Study in Patients With Haemophilia Treated wIth NovoEight® for Surgery","status":"COMPLETED","sponsor":"Nantes University Hospital","startDate":"2021-07-02","conditions":["Hemophilia"],"enrollment":60,"completionDate":"2022-06-30"},{"nctId":"NCT02546622","phase":"","title":"ATHN 2: Factor Switching Study","status":"COMPLETED","sponsor":"American Thrombosis and Hemostasis Network","startDate":"2015-09","conditions":["Hemophilia"],"enrollment":310,"completionDate":"2020-06-30"},{"nctId":"NCT03196297","phase":"PHASE2","title":"A Trial Evaluating Efficacy and Safety of Prophylactic Administration of Concizumab in Patients With Severe Haemophilia A Without Inhibitors","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2017-08-16","conditions":["Haemostasis","Haemophilia A"],"enrollment":36,"completionDate":"2020-06-03"},{"nctId":"NCT02207218","phase":"","title":"To Investigate Safety and Efficacy of NovoEight® (rFVIII) During Long-term Treatment of Haemophilia A in Japan","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2014-08-04","conditions":["Congenital Bleeding Disorder","Haemophilia A"],"enrollment":40,"completionDate":"2020-11-10"},{"nctId":"NCT03179748","phase":"","title":"Study Investigating Novoeight®/NovoEight® (Turoctocog Alfa) in Mexican Haemophilia A Patients","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2018-06-20","conditions":["Congenital Bleeding Disorder","Haemophilia A"],"enrollment":10,"completionDate":"2021-06-16"},{"nctId":"NCT01493778","phase":"PHASE3","title":"Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2012-09-17","conditions":["Congenital Bleeding Disorder","Haemophilia A"],"enrollment":60,"completionDate":"2018-12-05"},{"nctId":"NCT01731600","phase":"PHASE3","title":"A Multinational, Open-Label, Non-Controlled Trial on Safety, Efficacy and Pharmacokinetics of NNC 0129-0000-1003 in Previously Treated Paediatric Patients With Severe Haemophilia A","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2013-02-20","conditions":["Congenital Bleeding Disorder","Haemophilia A"],"enrollment":68,"completionDate":"2018-09-28"},{"nctId":"NCT01480180","phase":"PHASE3","title":"Evaluation of Safety and Efficacy, Including Pharmacokinetics, of NNC 0129-0000-1003 When Administered for Treatment and Prophylaxis of Bleeding in Subjects With Haemophilia A","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2012-01-30","conditions":["Congenital Bleeding Disorder","Haemophilia A"],"enrollment":186,"completionDate":"2018-12-10"},{"nctId":"NCT01489111","phase":"PHASE3","title":"Evaluating the Haemostatic Effect of NNC 0129-0000-1003 During Surgical Procedures in Subjects With Haemophilia A.","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2012-08-03","conditions":["Congenital Bleeding Disorder","Haemophilia A"],"enrollment":36,"completionDate":"2018-12-10"},{"nctId":"NCT02938585","phase":"PHASE3","title":"Efficacy and Safety of Turoctocog Alfa for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Chinese Patients With Haemophilia A","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2016-12-12","conditions":["Congenital Bleeding Disorder","Haemophilia A"],"enrollment":68,"completionDate":"2018-12-12"},{"nctId":"NCT03588741","phase":"PHASE3","title":"Evaluation of Safety Following Immune Tolerance Induction Treatment With Turoctocog Alfa in Patients With Haemophilia A Following Inhibitor Development in NN7170-4213 Trial","status":"TERMINATED","sponsor":"Novo Nordisk A/S","startDate":"2018-06-12","conditions":["Haemophilia A"],"enrollment":1,"completionDate":"2019-06-19"},{"nctId":"NCT02035384","phase":"","title":"Safety and Efficacy of Turoctocog Alfa During Long-Term Treatment of Severe and Moderately Severe Haemophilia A","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2014-06-05","conditions":["Congenital Bleeding Disorder","Haemophilia A"],"enrollment":69,"completionDate":"2020-01-15"},{"nctId":"NCT03449342","phase":"PHASE4","title":"Research Study to Look at Side Effects During Regular Injection With Factor VIII Medicine Named Turoctocog Alfa for a 8 Weeks Period","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2018-03-01","conditions":["Congenital Bleeding Disorder","Haemophilia A"],"enrollment":60,"completionDate":"2019-04-22"},{"nctId":"NCT02994407","phase":"PHASE1","title":"Safety, Tolerability, and Pharmacokinetics Study of Turoctocog Alfa Pegol Injected Under the Skin in Patients With Haemophilia A","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2017-01-30","conditions":["Congenital Bleeding Disorder","Haemophilia A"],"enrollment":50,"completionDate":"2018-10-15"},{"nctId":"NCT02941354","phase":"PHASE1","title":"Evaluating the Pharmacokinetics of NovoEight® (Turoctocog Alfa) in Relation to BMI in Subjects With Haemophilia A","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2016-10-10","conditions":["Congenital Bleeding Disorder","Haemophilia A"],"enrollment":35,"completionDate":"2017-06-20"},{"nctId":"NCT03405337","phase":"","title":"Evaluation of Patient and Physician Reported Reasons for Switching Factor VIII Replacement Therapies","status":"COMPLETED","sponsor":"Bayer","startDate":"2018-02-14","conditions":["Hemophilia A"],"enrollment":160,"completionDate":"2018-06-13"},{"nctId":"NCT02920398","phase":"PHASE1","title":"A Multi-centre, Comparative, Double Blind, Randomised Cross-over Trial Investigating Single Dose Pharmacokinetics and Safety of Turoctocog Alfa Pegol From the Pivotal Process and Turoctocog Alfa Pegol From the Commercial Process in Patients With Severe Haemophilia A","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2016-10-04","conditions":["Congenital Bleeding Disorder","Haemophilia A"],"enrollment":21,"completionDate":"2017-04-07"},{"nctId":"NCT00984126","phase":"PHASE3","title":"Safety and Efficacy of Turoctocog Alfa (N8) in Prevention and On-demand Treatment of Bleeding Episodes in Subjects With Haemophilia A: An Extension to Trials NN7008-3543, NN7008-3545, NN7008-3600, NN7008-3893 and NN7008-4015","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2009-10-26","conditions":["Congenital Bleeding Disorder","Haemophilia A"],"enrollment":214,"completionDate":"2016-06-29"},{"nctId":"NCT00840086","phase":"PHASE3","title":"Safety and Efficacy of Turoctocog Alfa in Haemophilia A Subjects","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2009-04","conditions":["Congenital Bleeding Disorder","Haemophilia A"],"enrollment":150,"completionDate":"2011-09"},{"nctId":"NCT01138501","phase":"PHASE3","title":"Safety and Efficacy of Turoctocog Alfa in Previously Treated Male Children With Haemophilia A","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2010-06","conditions":["Congenital Bleeding Disorder","Haemophilia A"],"enrollment":65,"completionDate":"2011-11"},{"nctId":"NCT00837356","phase":"PHASE1","title":"Comparison of the Action of Drugs in the Body and Safety of N8 and Advate® in Haemophilia A Subjects","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2009-03","conditions":["Congenital Bleeding Disorder","Haemophilia A"],"enrollment":23,"completionDate":"2009-10"},{"nctId":"NCT01238367","phase":"PHASE1","title":"A Single Dose Trial of Recombinant Factor VIII (N8) in Japanese Subjects With Haemophilia A: An Extension to Trial NN7008-3543","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2010-11","conditions":["Congenital Bleeding Disorder","Haemophilia A"],"enrollment":6,"completionDate":"2011-10"},{"nctId":"NCT01365520","phase":"PHASE1","title":"A Single Dose Trial of NNC 0155-0000-0004 in Patients With Haemophilia A","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2011-06","conditions":["Congenital Bleeding Disorder","Haemophilia A"],"enrollment":4,"completionDate":"2011-09"},{"nctId":"NCT01692925","phase":"PHASE1","title":"Investigation of the Pharmacokinetics of Turoctocog Alfa in Subjects With Haemophilia A","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2012-12","conditions":["Congenital Bleeding Disorder","Haemophilia A"],"enrollment":15,"completionDate":"2013-03"},{"nctId":"NCT01205724","phase":"PHASE1","title":"Safety and Pharmacokinetics of NNC 0129-0000-1003 in Subjects With Haemophilia A","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2010-09","conditions":["Congenital Bleeding Disorder","Haemophilia A"],"enrollment":27,"completionDate":"2011-04"}],"_emaApprovals":[{"date":"2013-11-13","status":"Authorised","company":"Novo Nordisk A/S"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"MMSL":"239004","NDDF":"002035","UNII":"969NZA3X9T","VANDF":"4019616","INN_ID":"9412","RXNORM":"1607560","UMLSCUI":"C3529563","chemblId":"CHEMBL2108286","ChEMBL_ID":"CHEMBL2108286","KEGG_DRUG":"D10227","DRUGBANK_ID":"DB09109","SNOMEDCT_US":"278910002","MESH_SUPPLEMENTAL_RECORD_UI":"C577506"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"","companyName":"Novo Nordisk","relationship":"Original Developer"},{"period":"2014","companyName":"Novo Nordisk Pharma Ltd.","relationship":"PMDA Licensee"}],"publicationCount":88,"therapeuticAreas":["Rare Disease"],"atcClassification":{"source":"DrugCentral","atcCode":"B02BD02","allCodes":["B02BD02","B02BD06"]},"biosimilarFilings":[],"originalDeveloper":"Novo Nordisk A/S","recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"approved","companyName":"Novo Nordisk","companyId":"novo-nordisk","modality":"Recombinant protein","firstApprovalDate":"2013","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"approved","approval_date":"2013-11-13T00:00:00.000Z","mah":"Novo Nordisk A/S","brand_name_local":"","application_number":""},{"country_code":"EU","regulator":"EMA","status":"approved","approval_date":"2013-11-13T00:00:00.000Z","mah":"Novo Nordisk A/S","brand_name_local":"NovoEight","application_number":"EMEA/H/C/002719"},{"country_code":"JP","regulator":"PMDA","status":"approved","approval_date":"2014-01-17T00:00:00.000Z","mah":"Novo Nordisk Pharma Ltd.","brand_name_local":null,"application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"JP","regulator":"PMDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"NovoEight","application_number":"NovoEight"}],"trialStats":{"total":4,"withResults":2},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:30:53.559406+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}